We serve Chemical Name:(E)-Methyl 4-chloro-3-methoxybut-2-enoate CAS:110104-60-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(E)-Methyl 4-chloro-3-methoxybut-2-enoate
CAS.NO:110104-60-4
Synonyms:2-Butenoic acid, 4-chloro-3-methoxy-, methyl ester, (2E)-;Methyl (2E)-4-chloro-3-methoxy-2-butenoate;(E)-4-Chloro-3-methoxy-2-butenoic Acid Methyl Ester;Methyl (2E)-4-chloro-3-methoxybut-2-enoate;Methyl (E)-4-Chloro-3-methoxy-2-butenoate
Molecular Formula:C6H9ClO3
Molecular Weight:164.587
HS Code:2918990090
Physical and Chemical Properties:
Melting point:25ºC
Boiling point:230.9±35.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.449
PSA:35.53000
Exact Mass:164.024017
LogP:0.90
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3261
Packing Group:III
Contact us for information like 2-Butenoic acid, 4-chloro-3-methoxy-, methyl ester, (2E)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methyl (E)-4-Chloro-3-methoxy-2-butenoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl (2E)-4-chloro-3-methoxy-2-butenoate Use and application,Methyl (2E)-4-chloro-3-methoxybut-2-enoate technical grade,usp/ep/jp grade.
Related News: “From the new company, we’ll be able to provide customers with invaluable access to high-quality sterile fill and finish capacity, which is in huge demand globally,” Recipharm CEO Marc Funk said in a release. [(2R,3S,5R)-4-fluoro-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate manufacturers GSK picked McNamara after six months of “extensive search and selection process,” GSK said in its announcement Thursday. It ran the quest with help from two headhunters and evaluated “several external and internal candidates,” it said. 2-(4′-nitrophenylamino)thiazole suppliers The outlay will be used to grow Takeda’s portfolio of treatments and boost capacity to manufacture additional products for the rare disease community, Stephen Hatke, Takeda’s Thousand Oaks site head, said in a YouTube video about the expansion. The company didn’t name the specific products it plans to make there. 1,4-Diacetoxy-2,5-dichlor-3,6-di(2)naphthyl-benzol vendor & factory.
